Occult Hypertension: The Silent Blood Pressure Problem That Makes Cancer Harder to Treat and Easier to Recur

For anyone facing cancer, or working to keep it from returning, blood pressure is rarely near the top of the list of concerns. That is understandable. The attention goes to scans, labs, side effects, and the next appointment. A number on a cuff feels like a problem for another decade.

It belongs closer to the top than most people realize, and for a reason that has little to do with the usual question.

The usual question is whether high blood pressure causes cancer. That debate is old, and it is largely beside the point for someone who already has a diagnosis. The question that matters far more, and that the research addresses with real mechanistic clarity, is different: once cancer exists, what does high blood pressure do to it?

The answer is that blood pressure shapes the environment the disease lives in. It influences how readily cancer cells travel and take hold in new tissue. It influences how much oxygen reaches a tumor, which in turn determines how well radiation works. It influences whether chemotherapy can physically penetrate the tissue it is meant to kill. It influences whether the immune system can reach the tumor at all. And after treatment ends, it influences how welcoming the body remains to any cells that survived.

Put simply: you cannot always control the seed. You can, however, influence the soil.

The body we have been given is beautifully designed, including the elegant system that keeps blood moving at just the right pressure through miles of vessels. But that design can be knocked out of balance, and part of stewarding this body well is measuring what actually matters rather than what is merely convenient to measure. That brings us to the second half of this article, a hidden form of high blood pressure that escapes the very test most people rely on.

Before we go further: this is educational content, not medical advice. Nothing here replaces the individualized judgment of your own physician and oncology team, and nothing here is a reason to start, stop, or change a medication on your own.

How hypertension helps cancer spread

Spread is not a single event. It is a sequence, and a cancer cell has to survive every step: break away, endure the bloodstream, attach somewhere new, and then grow there. Each step is easier in a body with high blood pressure, for three reasons that reinforce one another. The vessel walls become better landing sites. The tissue becomes oxygen-deprived, which selects for the most aggressive cells. And the whole system stays inflamed, which feeds tumor growth while quietly disarming the immune response meant to stop it.

Injured vessels become sticky landing sites

The inner lining of every blood vessel, called the endothelium, is not passive plumbing. It is an active, living surface, and one of its main jobs is producing nitric oxide, the molecule that keeps vessels relaxed, smooth, and non-adhesive. Chronic high blood pressure, driven substantially by a hormone called angiotensin II, injures that lining and reduces nitric oxide. Vessels tighten, oxidative stress rises, and inflammation follows.

An injured, inflamed lining also displays more docking molecules on its surface, such as VCAM-1 and ICAM-1. Their normal job is helping immune cells grab hold and exit the bloodstream where they are needed. Cancer cells traveling in the bloodstream can use those very same handholds to attach and slip out into new tissue, which is a decisive step in how cancer spreads. A vessel wall roughened by years of pressure is, in effect, a more hospitable landing site.

There is a nuance here that is more encouraging than the simple version. The bloodstream is actually a hostile place for cancer cells. The friction of flowing blood, called shear stress, kills the great majority of them. But a hardy minority survives, and research shows those survivors adapt in ways that make them tougher and more invasive. So the accurate statement is not that blood flow helps cancer. Rather, blood flow acts as a filter, and a stiff, high-pressure vascular system changes that filter in ways that favor the toughest cells.

Low oxygen makes tumors more aggressive

When arteries stiffen and narrow, they deliver less blood and therefore less oxygen. Tumors are often short on oxygen to begin with, because the vessels they build are chaotic and leaky. Add vascular disease on top of that, and the shortage compounds.

Low oxygen, called hypoxia, is one of the most powerful known drivers of aggressive cancer behavior. It flips a molecular switch called HIF-1-alpha, which tells the tumor to build new blood vessels, shift its metabolism, and take on a more stem-cell-like, invasive character. Cells that would otherwise stay put begin to loosen their grip on their neighbors and migrate, a process called epithelial-mesenchymal transition. Hypoxia also switches on survival pathways that help cancer cells resist the very treatments aimed at them.

This is the hinge on which much of the rest of the article turns. Poor perfusion is not a background detail. It actively selects for the most dangerous cells in the tumor and simultaneously blunts the therapies designed to remove them.

Chronic inflammation feeds growth and disables the immune response

High blood pressure is now understood to be, in part, an inflammatory condition. Angiotensin II raises inflammatory messengers such as IL-6 and TNF-alpha and activates a master inflammatory switch called NF-kB. The same signals that damage vessels also feed tumors, supporting cancer cell growth, survival, new blood vessel formation, and resistance to the natural process by which damaged cells are supposed to die.

Just as important is what this does to immune defenses. Inflamed, poorly oxygenated tumor environments recruit suppressive immune cells that shut down the attack and exhaust the killer T cells that are supposed to do the work. Abnormal tumor vessels physically keep T cells from getting in. This is precisely why researchers have become so interested in restoring healthier blood flow inside tumors, an approach called vascular normalization, as a way to make immune therapies work better.

How hypertension works against your treatment

This is the part with the most immediate practical weight, because it touches the therapy happening right now.

Radiation needs oxygen to work

Radiation kills cancer largely by generating oxygen-dependent free radicals that damage DNA in a way the cell cannot repair. Without enough oxygen present, the same dose accomplishes far less. Radiation oncologists have known this for decades and call it the oxygen effect. Hypoxic cells can require roughly two to three times the dose to achieve the same kill. A tumor kept chronically short of oxygen by stiff, narrowed vessels is, in a real sense, pre-armored against radiotherapy.

Drugs cannot reach what they cannot penetrate

Even an excellent drug cannot help if it cannot get to the tumor. Solid tumors build up remarkable internal pressure, partly from fluid trapped inside because their vessels leak and their drainage is compressed, and partly from the physical squeeze of densely packed cells and fibrous tissue. That pressure collapses vessels inside the tumor and flattens the gradient that normally pushes drugs out of the bloodstream and into tissue. Stiff, diseased vessels elsewhere in the body only add to the problem. Chemotherapy that circulates well in the blood can still reach the tumor at disappointing concentrations.

Immune therapies depend on access

Checkpoint inhibitors work by releasing the brakes on T cells so they can attack the tumor. That only helps if T cells can actually get inside. Endothelial dysfunction, chronic inflammation, and the abnormal vessels of a hypoxic tumor all reduce T cell trafficking while increasing the suppressive cell populations that shut the response down. Access is the bottleneck, and vascular health is a large part of access.

Toxicity forces the dose reductions nobody wants

Uncontrolled high blood pressure raises the risk of kidney injury, cardiac strain, and vascular complications during treatment. That matters enormously, because those complications are among the most common reasons doses get reduced or cycles get delayed. A dose reduction that could have been avoided is a real cost to outcomes. Blood pressure control is one of the few levers genuinely within reach before and during therapy, and it is worth pulling.

An important reassurance if your blood pressure rises during treatment

This part matters, and it should not be buried.

Several cancer drugs that block a growth signal called VEGF (including bevacizumab, lenvatinib, sunitinib, and sorafenib) commonly raise blood pressure as a side effect. If that has happened to you, do not read this article and conclude that your treatment is harming you.

The opposite is closer to the truth. When blood pressure rises during VEGF-blocking therapy, it is frequently a sign the drug is hitting its target. In metastatic colorectal cancer treated with bevacizumab, patients who developed high blood pressure had better response rates and substantially longer survival in a single-center analysis (median overall survival of 25.8 months compared with 11.7 months). Similar patterns have been reported with other drugs in this class.

That situation is fundamentally different from entering treatment carrying years of uncontrolled high blood pressure that has already stiffened the vessels and reduced oxygen delivery to the tissues. Treatment-emergent high blood pressure is something to monitor and manage carefully with your team, not something to fear. Longstanding, uncontrolled high blood pressure is something to correct.

Where blood pressure medicine and cancer biology overlap

The clearest bridge between these two worlds is the renin-angiotensin system, the hormone cascade that regulates blood pressure. Angiotensin II, acting through its AT1 receptor, also promotes tumor cell growth, new vessel formation, fibrosis, and spread in laboratory models. Higher AT1 receptor expression has been linked to more tumor blood vessel growth and worse survival in ovarian cancer.

That has turned an ordinary, inexpensive blood pressure pill into a serious subject of cancer research. Losartan, a common angiotensin receptor blocker, was shown by researchers at Harvard to reduce the dense collagen that clogs tumors and to improve how well therapy is distributed and how well it works in animal models. This directly addresses the drug-delivery problem described above. Later work extended the finding to improving perfusion, enhancing radiation, and supporting immunotherapy, and losartan has moved into human clinical trials alongside chemotherapy and radiation for pancreatic cancer.

Caution is warranted here, because hope and hype are easy to confuse. The human cancer data on blood pressure medications remain mixed and largely observational. Large randomized trial data have not shown an overall increase in cancer risk with angiotensin receptor blockers, though the picture is not perfectly settled. Propranolol, a beta-blocker that blunts stress-related adrenaline signaling, shows genuinely intriguing anti-spread activity in laboratory models and some supportive observational human data, but it is not an established cancer therapy. And hydrochlorothiazide, a very common diuretic, carries a well-documented, dose-related increase in squamous cell skin cancer risk because it makes skin more sensitive to sunlight, which is worth discussing with your doctor along with diligent sun protection.

The practical takeaway is not to chase a particular pill for its rumored cancer benefit. It is to control blood pressure well. If you and your physician are choosing among otherwise reasonable options, these considerations can inform that conversation.

Recurrence: The soil after the storm

Even when treatment appears to have worked, small numbers of cancer cells can remain, quiet and dormant. Whether they ever wake up depends heavily on the environment around them.

Persistent high blood pressure keeps that environment hospitable to relapse through the same three mechanisms already described. It maintains low oxygen, which favors the most aggressive surviving cells. It maintains inflammation, which supplies survival signals. And it maintains endothelial dysfunction, which makes it easier for dormant micrometastases to attract the new blood supply they need in order to grow.

The clinical evidence here deserves an honest reading. A 2025 systematic review and meta-analysis from the Japanese Society of Hypertension’s Onco-Hypertension working group, published in Hypertension Research, pooled 13 observational studies covering 50,549 cancer survivors. Overall, hypertension was not significantly associated with solid tumor recurrence (hazard ratio 1.09, 95% CI 0.97-1.22), though a significant association appeared in colorectal cancer in the subgroup analysis.

That is a more modest result than the biology alone might predict, and it should be reported as such rather than dressed up. It argues not for alarm, but for attention. The mechanisms are real and well characterized, the clinical signal is present but not overwhelming, and blood pressure control carries independent benefits for the heart, kidneys, and brain regardless of how the cancer question resolves. Blood pressure belongs in survivorship care, which is exactly the direction the field is moving.

For completeness: the older question of whether blood pressure raises cancer incidence has produced genuinely mixed answers. Large pooled cohorts have found modest associations, while more rigorous reviews have found the links inconsistent across most cancer types. That debate continues, but it is not the reason blood pressure deserves your attention if you are already navigating a diagnosis.

The hidden version: Occult, or masked, hypertension

Now to the part that most surprises people, including physicians.

You may have heard of white coat hypertension, where blood pressure spikes in the doctor’s office but is fine at home. Masked hypertension is its mirror image, and it is far more dangerous. In masked hypertension, the office reading looks reassuringly normal while blood pressure is genuinely high during ordinary daily life, and often during sleep. The defining feature is that mismatch: normal in the clinic, elevated outside it.

Because it hides from the one measurement most of us rely on, it often goes undetected for years while quietly straining the heart, kidneys, and blood vessels. The 2017 American College of Cardiology and American Heart Association guideline reports that the risk of cardiovascular disease and death in people with masked hypertension is similar to that in people with ordinary sustained hypertension, and about twice as high as in people whose blood pressure is genuinely normal.

This is not a rare curiosity. Prevalence runs about 10-30% depending on the population studied. For a cancer patient, it means the vascular problems described throughout this article could be operating quietly while every clinic reading says otherwise.

The numbers that define it

Diagnosing masked hypertension requires measuring blood pressure outside the clinic, because by definition the clinic misses it. The thresholds most widely used in research come from European criteria and are worth writing down. Home blood pressure at or above 135/85 mmHg. Daytime ambulatory blood pressure at or above 135/85 mmHg. Nighttime ambulatory blood pressure at or above 120/70 mmHg. Twenty-four hour average ambulatory blood pressure at or above 130/80 mmHg.

American readers should know that US guidelines use somewhat lower cutoffs. The 2017 ACC/AHA guideline lowered the office threshold for hypertension to 130/80 mmHg and set out-of-office values at 130/80 for home and daytime readings, 125/75 for the 24-hour average, and 110/65 at night. European guidelines (2023 ESH and 2024 ESC) still diagnose hypertension in the office at 140/90 mmHg, and the 2024 European guideline added a middle category it calls elevated blood pressure, from 120-139 over 70-89 mmHg, where treatment depends on overall risk.

The differences are real but modest, and every major guideline now agrees on the central point. Measuring blood pressure outside the clinic is essential, not optional.

Why the 24-hour monitor beats the home cuff

Two ways to measure outside the office exist. Home monitoring uses a validated cuff you operate yourself, typically morning and evening for several days. Ambulatory monitoring uses a device worn for 24 hours that takes readings automatically, day and night, including during sleep.

Both help, but they are not equivalent, and one study makes the difference vivid. In the Improving the Detection of Hypertension study, published in Hypertension in 2018, 333 adults with normal clinic readings underwent both. Ambulatory monitoring found masked hypertension in 25.8%. Home monitoring found it in only 11.1%. Of everyone identified by either method, 61.1% were caught only by ambulatory monitoring.

Here is the part that matters most. The people ambulatory monitoring caught already had measurably thicker heart muscle, an early sign of strain. Those identified by home monitoring alone did not. Ambulatory monitoring did not just find more cases. It found the cases that were already doing damage.

The insight worth remembering: it is often a nighttime problem

Much of masked hypertension is nighttime hypertension, or a pattern called non-dipping, in which blood pressure fails to fall during sleep the way it is designed to. Normally, pressure should drop by at least 10% overnight, giving the heart and vessels a genuine period of rest. When that dip does not happen, or when pressure actually rises at night, the pattern strongly predicts heart attacks, strokes, and death.

No clinic visit can see this. No daytime home reading can see this. Only a 24-hour monitor can.

Nighttime blood pressure is also tightly connected to sleep apnea, a condition that raises blood pressure and independently worsens inflammation and metabolic health, both of which feed the tumor environment described earlier. If blood pressure will not come down at night, untreated sleep apnea is one of the first things worth investigating.

Who should be checked?

Masked hypertension is more common in younger adults whose office readings sit at the high end of normal, in smokers, in people with diabetes, in people carrying excess weight, and in anyone showing unexplained organ strain despite normal clinic numbers.

For cancer patients and survivors, several more groups belong on that list. Anyone about to begin treatment that stresses the heart, kidneys, or blood vessels. Anyone taking a VEGF-blocking drug. Anyone entering survivorship, particularly after treatments known to leave lasting cardiovascular effects. And frankly, anyone who wants to be certain that a normal-looking reading is telling the truth.

The workflow is straightforward. Confirm the office reading is truly normal using multiple careful measurements. Request 24-hour ambulatory monitoring, or structured home monitoring if ambulatory is unavailable. Diagnose masked hypertension if any out-of-office threshold is exceeded, including the nighttime value. Check for early organ strain, such as heart muscle thickening or protein in the urine. Then treat according to overall risk, in partnership with your physician.

What you can actually do

Blood pressure control is one of the highest-value, lowest-risk things within reach, and every step below independently supports a healthier internal environment. None of these is a cancer treatment, and none replaces prescribed therapy. Their power is cumulative, and their downside is close to zero.

• Eat a whole-food, plant-forward pattern. The landmark DASH trial lowered blood pressure by 5.5/3.0 mmHg overall, and by 11.4/5.5 mmHg among people who already had hypertension. Adding sodium reduction to that pattern lowered the top number by 11.5 mmHg in people with hypertension. Think less processed salt and far more potassium-rich vegetables, fruits, and legumes.
• Eat nitrate-rich vegetables. Leafy greens and beets supply the raw material for nitric oxide, the molecule that keeps vessels relaxed and their lining non-adhesive. A meta-analysis found dietary nitrate lowered the top number by about 4.4 mmHg.
• Move, and build aerobic fitness. Endurance exercise lowered blood pressure by 3.5/2.5 mmHg overall in a large meta-analysis, and by 8.3/5.2 mmHg in people who already had hypertension. Ask your oncology team what level of activity is appropriate right now, since the answer changes across treatment.
• Lose excess weight if you carry it. Blood pressure falls roughly 1 mmHg for every kilogram lost.
• Reduce alcohol. Among heavier drinkers, cutting intake in half lowered blood pressure by 5.5/4.0 mmHg.
• Protect your sleep and treat sleep apnea. CPAP therapy lowers blood pressure modestly overall, with the greatest benefit on the dangerous nighttime numbers and in people with severe apnea or hard-to-control hypertension.
• Get magnesium, mostly from food. Supplementation produced a modest reduction of about 2.0/1.8 mmHg. Nuts, seeds, legumes, and greens come first, and any supplement should be discussed with your physician, particularly during active treatment.
• Tend to stress and rest. Chronic activation of the stress response raises blood pressure, and the propranolol research hints that adrenaline signaling may touch tumor biology as well. Prayer, genuine rest, and real community are not soft extras layered on top of the medicine. They are part of caring well for the body you have been entrusted with.

What to ask your doctor

Appointments are short, and blood pressure rarely comes up on its own when there is a scan to review or a treatment cycle to plan. That makes it worth arriving with the questions already written down. The five below take only a minute or two to raise, and each one targets a decision your physician can act on:

• Is 24-hour ambulatory monitoring warranted for me? This matters most when office readings look normal, but risk factors are present, or when there is any question of nighttime hypertension.
• Should I be checked for early organ strain? Heart muscle thickening and protein in the urine are two of the earliest signs that pressure has been quietly doing damage.
• How will my blood pressure be monitored and controlled during treatment? Ask this if you are in or approaching therapy, particularly with a VEGF-blocking drug, an anthracycline, trastuzumab, or cisplatin. Also ask what reading would trigger a dose adjustment.
• Can you include blood pressure in my long-term follow-up plan? If you are entering survivorship, ask for it to be part of the plan rather than an afterthought.
• Is the skin cancer signal with hydrochlorothiazide relevant to me? Worth asking if you take it, and worth being diligent about sun protection either way.

How to measure blood pressure correctly at home

Use a validated upper-arm cuff, not a wrist or finger device. Sit quietly for five minutes first, with the back supported, feet flat on the floor, and arm resting at heart level. Skip caffeine, exercise, and tobacco for 30 minutes beforehand, and empty the bladder. Take two readings a minute apart, morning and evening, for at least several days in a row. Write down every reading, including the unwelcome ones, and bring the log to appointments.

One caution worth repeating: home monitoring is a good screen, but it misses most cases that a 24-hour monitor catches. A normal home average is encouraging. It is not final proof.

A closing word

So much of the energy in this fight goes toward the parts that feel out of reach. Blood pressure is not one of those parts. It is measurable, modifiable, and largely within your influence, and it touches nearly every mechanism that determines how far cancer travels, how well treatment penetrates, and how welcoming the body remains once treatment ends.

If clinic readings have always been normal, that is genuinely good news, and it may be the whole story. But it may not be. Ask one question at the next appointment about whether a 24-hour monitor makes sense; it costs nothing and could uncover something that has been hiding for years.

You are not merely a patient managing numbers. You are a person caring for a body that was designed with remarkable wisdom, and paying attention to it is a form of faithfulness. Take heart, ask the question, and keep going.

This article is for education only and is not a substitute for individualized medical advice, diagnosis, or treatment. Please consult your own physician and oncology team before making any changes to your care.

References

1. Anstey DE, Muntner P, Bello NA, et al. Diagnosing masked hypertension using ambulatory blood pressure monitoring, home blood pressure monitoring, or both? Hypertension. 2018;72(5):1200-1207.
2. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336(16):1117-1124.
3. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29(19):2635-2644.
4. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension. 2007;50(2):417-423.
5. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473.
6. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A. 2011;108(7):2909-2914.
7. Gao X, Zhao Y, Stemmer-Rachamimov AO, et al. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021;13(602):eabd4816.
8. Guo X, Zhang Y, Wang P, et al. Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis. Br J Cancer. 2022;127(9):1620-1628.
9. Kim HL, Kim SH. Impact of 2018 ESC/ESH and 2017 ACC/AHA hypertension guidelines: difference in prevalence of white-coat and masked hypertension. Healthcare (Basel). 2020;8(2):122.
10. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications.
11. Lin YT, Wang HC, Tsai MC, et al. Non-dipping blood pressure or nocturnal hypertension: does one matter more? Curr Hypertens Rep. 2023;25(12):469-480.
12. Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):C82-C97.
13. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878-884.
14. Okazaki Y, Komura N, Minegishi S, et al. Hypertension and risk of cancer recurrence in adult survivors: a systematic review and meta-analysis. Hypertens Res. 2026;49(3):949-957.
15. Österlund P, Soveri LM, Isoniemi H, et al. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011;104(4):599-604.
16. Pedersen SA, Gaist D, Schmidt SAJ, Hölmich LR, Friis S, Pottegård A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark. J Am Acad Dermatol. 2018;78(4):673-681.
17. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2(2):e108-e120.
18. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10.
19. Seretis A, Cividini S, Markozannes G, et al. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep. 2019;9(1):8565.
20. Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143(6):818-826.
21. Stocks T, Van Hemelrijck M, Manjer J, et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension. 2012;59(4):802-810.
22. Suganuma T, Ino K, Shibata K, et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer. 2005;92(3):525-532.
23. van der Kooy K, et al. Skin cancer and hydrochlorothiazide: novel population-based analyses considering personal risk factors including race/ethnicity. Hypertension. 2024.
24. Wang Y, et al. Blocking VCAM-1 prevents angiotensin II-induced hypertension and vascular remodeling in mice.
25. Welter M, Rieger H. Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PLoS One. 2013;8(8):e70395.
26. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13-e115.
27. Williamson JD, et al. What is new and different in the 2024 European Society of Cardiology guidelines for the management of elevated blood pressure and hypertension? Hypertension. 2024.
28. Xu J, et al. Fluid shear stress regulates the survival of circulating tumor cells via nuclear expansion. J Cell Sci. 2022;135(10):jcs259586.
29. Zhang X, Li Y, Del Gobbo LC, et al. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension. 2016;68(2):324-333.
30. Zhang Z, et al. What did we learn from the International Databases on Ambulatory and Home Blood Pressure in Relation to Cardiovascular Outcome? Hypertens Res. 2023;46(7):1738-1750.
31. Zheng Y, et al. Immunomodulatory activity of cytokines in hypertension: a vascular perspective. Hypertension. 2024.